Inovio Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Inovio Pharmaceuticals's earnings have been declining at an average annual rate of -15%, while the Biotechs industry saw earnings growing at 15.7% annually. Revenues have been declining at an average rate of 31.3% per year.
Key information
-15.0%
Earnings growth rate
5.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -31.3% |
| Return on equity | -115.1% |
| Net Margin | -16,239.9% |
| Next Earnings Update | 13 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Inovio Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -135 | 48 | 0 |
| 30 Sep 23 | 1 | -165 | 51 | 0 |
| 30 Jun 23 | 10 | -168 | 53 | 0 |
| 31 Mar 23 | 10 | -241 | 88 | 0 |
| 31 Dec 22 | 10 | -280 | 76 | 0 |
| 30 Sep 22 | 11 | -332 | 90 | 0 |
| 30 Jun 22 | 2 | -355 | 92 | 0 |
| 31 Mar 22 | 2 | -328 | 56 | 0 |
| 31 Dec 21 | 2 | -304 | 54 | 0 |
| 30 Sep 21 | 7 | -221 | 48 | 0 |
| 30 Jun 21 | 6 | -142 | 45 | 0 |
| 31 Mar 21 | 6 | -188 | 44 | 0 |
| 31 Dec 20 | 7 | -166 | 37 | 0 |
| 30 Sep 20 | 2 | -180 | 37 | 0 |
| 30 Jun 20 | 3 | -222 | 33 | 0 |
| 31 Mar 20 | 3 | -123 | 28 | 0 |
| 31 Dec 19 | 4 | -119 | 27 | 0 |
| 30 Sep 19 | 6 | -115 | 24 | 0 |
| 30 Jun 19 | 7 | -117 | 25 | 0 |
| 31 Mar 19 | 32 | -94 | 27 | 0 |
| 31 Dec 18 | 30 | -97 | 29 | 0 |
| 30 Sep 18 | 37 | -86 | 32 | 0 |
| 30 Jun 18 | 37 | -95 | 31 | 0 |
| 31 Mar 18 | 33 | -97 | 30 | 0 |
| 31 Dec 17 | 42 | -88 | 28 | 0 |
| 30 Sep 17 | 42 | -93 | 27 | 0 |
| 30 Jun 17 | 52 | -80 | 27 | 0 |
| 31 Mar 17 | 38 | -89 | 26 | 0 |
| 31 Dec 16 | 35 | -74 | 24 | 0 |
| 30 Sep 16 | 33 | -65 | 22 | 0 |
| 30 Jun 16 | 44 | -39 | 20 | 0 |
| 31 Mar 16 | 44 | -27 | 19 | 0 |
| 31 Dec 15 | 41 | -29 | 18 | 0 |
| 30 Sep 15 | 37 | -19 | 17 | 0 |
| 30 Jun 15 | 15 | -31 | 16 | 0 |
| 31 Mar 15 | 13 | -36 | 16 | 0 |
| 31 Dec 14 | 10 | -36 | 16 | 0 |
| 30 Sep 14 | 10 | -44 | 16 | 0 |
| 30 Jun 14 | 17 | -68 | 16 | 0 |
| 31 Mar 14 | 14 | -68 | 15 | 0 |
| 31 Dec 13 | 13 | -66 | 14 | 0 |
| 30 Sep 13 | 13 | -51 | 12 | 0 |
| 30 Jun 13 | 4 | -27 | 12 | 0 |
Quality Earnings: GBM is currently unprofitable.
Growing Profit Margin: GBM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GBM is unprofitable, and losses have increased over the past 5 years at a rate of 15% per year.
Accelerating Growth: Unable to compare GBM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GBM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: GBM has a negative Return on Equity (-115.14%), as it is currently unprofitable.